Earnings Call Summary | Cytosorbents(CTSO.US) Q4 2023 Earnings Conference
Earnings Call Summary | Cytosorbents(CTSO.US) Q4 2023 Earnings Conference
The following is a summary of the CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript:
以下是 CytoSorbents Corporation (CTSO) 2023 年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
CytoSorbents Corporation reported a revenue of $36.3 million for the year, a 5% increase year-over-year.
CytoSorb product sales increased by 9% to $31 million in 2023.
The Q4 2023 saw an 8% decrease in total revenue and a 1% decrease in CytoSorb product sales.
The gross margin increased from 70% in 2022 to 72% in 2023 and is projected to continue improving.
The company closed the year with $15.6 million in cash reserves.
CytoSorbents公司報告稱，該年度的收入爲3630萬美元，同比增長5％。
2023 年，CytoSorb 的產品銷售額增長了 9%，達到 3100 萬美元。
2023年第四季度，總收入下降了8％，CytoSorb產品銷售額下降了1％。
毛利率從2022年的70％增加到2023年的72％，預計將繼續提高。
該公司以1,560萬澳元的現金儲備在年底結束。
Business Progress:
業務進展：
CytoSorbents delivered over 228,000 CytoSorb treatments by the end of 2023, a 17% increase from 2022.
The company formed a strategic partnership with Eris Lifesciences for CytoSorb in India.
It plans to launch the PuriFi pump post their agreement expiration with Nikkiso Europe GmbH.
CytoSorbents is set to submit applications for regulatory approval to the U.S. FDA and Health Canada in 2024's second half.
The company launched VetResQ to several regional veterinary centers in 2023 with plans for an integrated solution in 2024.
Progress was made on the HemoDefend-BGA prototype aimed at creating universal plasma.
Cost-saving measures aim to reduce the cash burn rate to around $3 million a quarter by the latter half of 2024.
截至 2023 年底，CytoSorbents 提供了超過 228,000 次 CytoSorb 治療，比 2022 年增長了 17%。
該公司與Eris Lifesciences在印度建立了CytoSorb的戰略合作伙伴關係。
它計劃在與Nikkiso Europe GmbH的協議到期後推出PuriFi泵。
CytoSorbents定於2024年下半年向美國食品藥品管理局和加拿大衛生部提交監管批准申請。
該公司於2023年在多個區域獸醫中心推出了VetreSQ，並計劃在2024年推出綜合解決方案。
旨在製造通用等離子體的Hemodefend-BGA原型取得了進展。
節省成本的措施旨在到2024年下半年將現金消耗率降低到每季度300萬美元左右。
More details: Cytosorbents IR
更多詳情： 細胞吸附劑 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。